Evidence map›Paper›PMID 39665305›Full record

ArticleCurrent medicinal chemistry2025

FHL1 Inhibition by miR-1301-3p Promotes Uterine Corpus Endometrial Carcinoma Cell Proliferation and Migration: A Prognostic Insight.

Mengna Zhu, Buze Chen, Lu Miao, Jieyun Sun, Yuanyuan Li, Pei Zhang, Xiaoyuan Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengna ZhuGraduate School, Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.ORCID 0009-0009-2373-8183
Buze ChenDepartment of Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.ORCID 0000-0002-3864-6910
Lu MiaoDepartment of Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.ORCID 0000-0002-4490-2087
Jieyun SunDepartment of Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.ORCID 0009-0006-1512-9677
Yuanyuan LiGraduate School, Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.ORCID 0009-0003-9489-6636
Pei ZhangGraduate School, Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.ORCID 0009-0001-3744-6685
Xiaoyuan LuDepartment of Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, Jiangsu, China.ORCID 0000-0001-5839-0804

Funding

Key R & D Plan (Social Development) Project of Xuzhou Science and Technology Bureau KC22246
6 · The paper itself

Abstract

backgroundThe impact of microRNA-1301-3p (miR-1301-3p) on various cancer subtypes is noteworthy. However, its specific role within the framework of uterine corpus endometrial carcinoma (UCEC) is yet to be clearly defined.

objectiveThe objective of this research was to investigate and clarify the function of miR-1301-3p in relation to UCEC.

methodsSample data for our study were sourced from The Cancer Genome Atlas (TCGA). Using various statistical techniques, we assessed the potential of miR-1301-3p as a diagnostic and prognostic indicator, as well as its association with clinical characteristics. Additionally, we conducted an analysis of the genes targeted by miR-1301-3p. The expression levels of miR-1301-3p in uterine corpus endometrial carcinoma (UCEC) cell lines were determined by quantitative real-time PCR (qRT-PCR). Cellular viability and migratory capacity were measured using the CCK8 assay and Transwell migration assays, respectively. Moreover, the expression levels of genes and proteins targeted by miR-1301-3p were identified through dual-luciferase reporter gene assays and Western blot analysis.

resultsExpression patterns of miR-1301-3p varied across cancer subtypes, which were significantly linked to specific histological classifications, achieving statistical significance (p < 0.001). In UCEC, higher miR-1301-3p levels correlated with reduced overall survival (p = 0.012) and progression-free survival (p = 0.016), and it emerged as an independent prognostic marker for UCEC. A comparative analysis revealed significantly higher miR-1301-3p levels in UCEC cell lines compared to normal endometrial epithelial cells. Four and a half LIM domains 1 (FHL1) exhibited a negative correlation with miR-1301-3p levels within UCEC tissue samples. miR-1301-3p was shown to promote UCEC cell proliferation and migration through its binding to the 3'-untranslated region (UTR) of the FHL1 gene, thereby repressing FHL1 expression. Additionally, augmenting FHL1 levels was observed to counteract the enhancing impact of miR-1301-3p on UCEC cells.

conclusionmiR-1301-3p regulates the proliferation and migration of UCEC cells by interacting with the FHL1 gene. miR-1301-3p may serve as a promising prognostic biomarker in UCEC.

Indexed as

Endometrial NeoplasmsIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMicroRNAsMuscle ProteinsCell Line, TumorCell MovementCell ProliferationFemaleHumansPrognosisIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMicroRNAsMIRN1301 microRNA, humanMuscle Proteinsbioinformaticsbiomarker.FHL1microRNA-1301-3pprognosisuterine corpus endometrial carcinoma (UCEC)

Identifiers

PMID39665305

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.